British Pharmacological Association Awards Major Prize to Founder of Antibe Therapeutics

CALGARY, ALBERTA, January 2, 2007 — Dr. John Wallace, Antibe founder and Chief Science Officer, has is the 2006 recipient of the Gaddum Memorial Award from the British Pharmacological Society.  Earlier in 2006, Dr. Wallace received the Senior Scientist Award from the Pharmacological Society of Canada. This is the Pharmacological Society of Canada’s highest annual award.

About the British Pharmacological Society

The British Pharmacological Society is one of the leading pharmacological societies in the world. The object of the Society is to promote and advance pharmacology, including clinical pharmacology. The Society created the Gaddum Memorial Prize in 1966. The award is made every two years for important contributions in the field of pharmacology or a related subject.

About Antibe Therapeutics, Inc.

Antibe (pronounced ‘on-teeb ’) Therapeutics (www.antibe-therapeutics.com) is a privately-held early-stage drug development company headquartered in Calgary , Canada with affiliate laboratories in the USA , United Kingdom , Italy and Brazil . The Company's pipeline consists of drugs targeting serious chronic diseases, including inflammatory bowel disease, erectile dysfunction, irritable bowel syndrome, pulmonary hypertension and various complications of diabetes.

Antibe's drug development platform involves the assimilation of small vasoactive/immunomodulatory components to existing drugs to generate new chemical entities that are significantly improved over the parent molecules and/or serve unmet medical needs.

With more than 50 years combined experience in the pharmaceutical and biotech sectors, Antibe's senior management team has a well-defined track record in the development of anti-inflammatory and vasoactive drugs, for which they have received approval from various regulatory boards inclusive of the US FDA.

For further information please contact:

Dan Legault
President and CEO
Antibe Therapeutics, Inc
(416) 849-8115